Association of Titin Variations With Late-Onset Dilated Cardiomyopathy.


Journal

JAMA cardiology
ISSN: 2380-6591
Titre abrégé: JAMA Cardiol
Pays: United States
ID NLM: 101676033

Informations de publication

Date de publication:
01 04 2022
Historique:
pubmed: 10 2 2022
medline: 16 4 2022
entrez: 9 2 2022
Statut: ppublish

Résumé

Dilated cardiomyopathy (DCM) is frequently caused by genetic factors. Studies identifying deleterious rare variants have predominantly focused on early-onset cases, and little is known about the genetic underpinnings of the growing numbers of patients with DCM who are diagnosed when they are older than 60 years (ie, late-onset DCM). To investigate the prevalence, type, and prognostic impact of disease-associated rare variants in patients with late-onset DCM. A population of patients with late-onset DCM who had undergone genetic testing in 7 international tertiary referral centers worldwide were enrolled from March 1990 to August 2020. A positive genotype was defined as the presence of pathogenic or likely pathogenic (P/LP) variants. The study outcome was all-cause mortality. A total of 184 patients older than 60 years (103 female [56%]; mean [SD] age, 67 [6] years; mean [SD] left ventricular ejection fraction, 32% [10%]) were studied. Sixty-six patients (36%) were carriers of a P/LP variant. Titin-truncating variants were the most prevalent (present in 46 [25%] of the total population and accounting for 46 [69%] of all genotype-positive patients). During a median (interquartile range) follow-up of 42 (10-115) months, 23 patients (13%) died; 17 (25%) of these were carriers of P/LP variants, while 6 patients (5.1%) were genotype-negative. Late-onset DCM might represent a distinct subgroup characterized by and a high genetic variation burden, largely due to titin-truncating variants. Patients with a positive genetic test had higher mortality than genotype-negative patients. These findings support the extended use of genetic testing also in older patients.

Identifiants

pubmed: 35138330
pii: 2788570
doi: 10.1001/jamacardio.2021.5890
pmc: PMC8829739
doi:

Substances chimiques

Connectin 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

371-377

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL069071
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL116906
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL147064
Pays : United States

Auteurs

Antonio Cannatà (A)

Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste, Trieste, Italy.
Department of Cardiovascular Sciences, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom.
Department of Cardiology, King's College Hospital, London, United Kingdom.

Marco Merlo (M)

Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste, Trieste, Italy.

Matteo Dal Ferro (M)

Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste, Trieste, Italy.

Giulia Barbati (G)

Biostatistics Unit, University of Trieste, Trieste, Italy.

Paolo Manca (P)

Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste, Trieste, Italy.

Alessia Paldino (A)

Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste, Trieste, Italy.

Sharon Graw (S)

Cardiovascular Institute and Adult Medical Genetics Program, University of Colorado Anschutz Medical Campus, Aurora.

Marta Gigli (M)

Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste, Trieste, Italy.

Davide Stolfo (D)

Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste, Trieste, Italy.

Renee Johnson (R)

Molecular Cardiology Division, Victor Chang Cardiac Research Institute, Darlinghurst, New South Wales, Australia.
Faculty of Medicine, UNSW Sydney, Kensington, New South Wales, Australia.
Cardiology Department, St Vincent's Hospital, Darlinghurst, New South Wales, Australia.

Darius Roy (D)

Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Kevin Tharratt (K)

Center for Inherited Heart Disease, Stanford University, Stanford, California.

Daniel I Bromage (DI)

Department of Cardiovascular Sciences, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom.
Department of Cardiology, King's College Hospital, London, United Kingdom.

Jean Jirikowic (J)

Cardiovascular Institute and Adult Medical Genetics Program, University of Colorado Anschutz Medical Campus, Aurora.

Antonio Abbate (A)

VCU Pauley Heart Center, Virginia Commonwealth University, Richmond.

Allison Goodwin (A)

VCU Medical Center, Clinical Genetics Services, Richmond, Virginia.

Krishnasree Rao (K)

VCU Pauley Heart Center, Virginia Commonwealth University, Richmond.

Amr Marawan (A)

VCU Pauley Heart Center, Virginia Commonwealth University, Richmond.

Gerry Carr-White (G)

Department of Cardiology, Guys and St Thomas' NHS Trust, London, United Kingdom.

Leema Robert (L)

Department of Clinical Genetics, Guys and St Thomas' NHS Trust, London, United Kingdom.

Victoria Parikh (V)

Center for Inherited Heart Disease, Stanford University, Stanford, California.

Euan Ashley (E)

Center for Inherited Heart Disease, Stanford University, Stanford, California.

Theresa McDonagh (T)

Department of Cardiovascular Sciences, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom.
Department of Cardiology, King's College Hospital, London, United Kingdom.

Neal K Lakdawala (NK)

Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Diane Fatkin (D)

Molecular Cardiology Division, Victor Chang Cardiac Research Institute, Darlinghurst, New South Wales, Australia.
Faculty of Medicine, UNSW Sydney, Kensington, New South Wales, Australia.
Cardiology Department, St Vincent's Hospital, Darlinghurst, New South Wales, Australia.

Matthew R G Taylor (MRG)

Cardiovascular Institute and Adult Medical Genetics Program, University of Colorado Anschutz Medical Campus, Aurora.

Luisa Mestroni (L)

Cardiovascular Institute and Adult Medical Genetics Program, University of Colorado Anschutz Medical Campus, Aurora.

Gianfranco Sinagra (G)

Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), University of Trieste, Trieste, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH